Key indicators: single-crystal X-ray study; T = 100 K; mean (C-C) = 0.002 Å; R factor = 0.046; wR factor = 0.132; data-to-parameter ratio = 23.4.
Related literature
For related literature, see: Calabresi et al. (1975) ; El-Hashash et al. (1993) ; Huang & Huang (2002) ; Marquez & Russ (2002) ; Townsend & Drach (2002) . For related structures and background to various derivatives of 4,4 0 -difluorochalcone, see: Fun et al. (2010a Fun et al. ( ,b, 2011 Fun et al. ( , 2012 . For the stability of the temperature controller used for data collection, see: Cosier & Glazer (1986) . For ring conformations and ring puckering analysis, see: Cremer & Pople (1975) . For reference bond lengths, see: Allen et al. (1987) . Refinement R[F 2 > 2(F 2 )] = 0.046 wR(F 2 ) = 0.132 S = 1.04 8234 reflections 352 parameters H-atom parameters constrained Á max = 0.47 e Å À3 Á min = À0.23 e Å À3 Table 1 Hydrogen-bond geometry (Å , ).
Cg5 is the centroid of the C20-C25 benzene ring. Symmetry codes: (i) x; y À 1; z þ 1; (ii) Àx þ 1; Ày þ 2; Àz; (iii) x; y À 1; z; (iv) Àx þ 1; Ày þ 1; Àz.
Data collection: APEX2 (Bruker, 2009); cell refinement: SAINT (Bruker, 2009); data reduction: SAINT; program(s) used to solve structure: SHELXTL (Sheldrick, 2008); program(s) used to refine structure: SHELXTL; molecular graphics: SHELXTL; software used to prepare material for publication: SHELXTL and PLATON (Spek, 2009). supplementary materials Acta Cryst. (2012) . E68, o807-o808 [doi:10.1107/S1600536812006976] 2-[3,5-Bis(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl]-4,6-bis(4-fluoro-
phenyl)pyrimidine
Hoong-Kun Fun, Tze Shyang Chia, S. Samshuddin, B. Narayana and B. K. Sarojini
Comment
The importance of pyrimidines and analogous compounds in pharmaceutical and biological fields is well known (Townsend & Drach, 2002) . Some substituted pyrimidines and their derivatives have been reported to possess antimicrobial and antifungal activities (El-Hashash et al., 1993) . It has incidental antiviral activity against herpes and vaccinia infections (Calabresi et al., 1975) . With the development of clinically useful pyrimidine-based antitumor (Huang & Huang, 2002) and antiviral (Marquez & Russ, 2002) drugs, there has been noticeable interest in synthetic manipulations of pyrimidines. In view of the biological importance of pyrimidines and in continuation of our work on synthesis of various derivatives of 4,4′-difluoro chalcone (Fun et al., 2010a,b; 2011; 2012) , the title compound is prepared and its crystal structure is reported.
The molecular structure of the title compound is shown in Fig. 1 . The pyrazole ring (N3/N4/C17-C19) adopts an envelope conformation [puckering parameters Q = 0.1757 (11) Å and φ = 135.8 (4)° (Cremer & Pople, 1975) ] and forms a dihedral angle of 9.91 (6)° with the adjacent pyrimidine ring (N1/N2/C7-C10) (maximum deviation = 0.011 (1) Å at atom N1). The pyrimidine ring forms dihedral angles of 9.23 (6) and 2.16 (5)° with its adjacent fluoro-substituted benzene rings (C1-C6 & C11-C16, respectively), whereas for pyrazole ring these angles are 88.22 (6) and 9.66 (6)° (C20-C25 & C26-C31, respectively). In the crystal packing, the molecules are linked by intermolecular C-H···F hydrogen bonds into ribbons along [01-1]. The crystal packing is further stabilized by C-H···π interactions (Table 1) , involving Cg5 which is the centroid of C20-C25 ring. π-π interactions are also observed with Cg2···Cg4 = 3.7428 (7) Å (symmetry code = 1-X,1-Y,-Z) and Cg2···Cg6 = 3.7630 (6) Å (symmetry code = 2-X,2-Y,-Z), where Cg2, Cg4 and Cg6 are the centroids of N1/N2/C7-C10, C11-C16 and C26-C31 rings, respectively.
Experimental
A mixture of 4,4′-difluoro chalcone (2.44 g, 0.01 mol) and amino guanidine hydrochloride (0.065 g, 0.005 mol) in 25 ml e thanol was refluxed for 24 h in the presence of sodium ethoxide (2 ml). The reaction mixture was cooled to room temperature and refrigerated overnight. The solid product obtained was filtered and recrystallized from ethanol to get a yellow powder. The single crystals were grown from MDC by slow evaporation method and the yield of the compound was 49% (m.p.: 548 K).
Refinement
All H atoms were positioned geometrically (C-H = 0.93, 0.97 or 0.98 Å) and refined using a riding model, with U iso (H) = 1.2U eq (C).
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Computing details
Data collection: APEX2 (Bruker, 2009); cell refinement: SAINT (Bruker, 2009); data reduction: SAINT (Bruker, 2009); program(s) used to solve structure: SHELXTL (Sheldrick, 2008); program(s) used to refine structure: SHELXTL (Sheldrick, 2008); molecular graphics: SHELXTL (Sheldrick, 2008); software used to prepare material for publication:
SHELXTL (Sheldrick, 2008) and PLATON (Spek, 2009).
Figure 1
The molecular structure of the title compound with atom labels and 50% probability displacement ellipsoids. supplementary materials sup-3 Acta Cryst. (2012). E68, o807-o808
Figure 2
The crystal packing of the title compound. The dashed lines represent the hydrogen bonds. For clarity sake, hydrogen atoms not involved in hydrogen bonding have been omitted. Refinement. Refinement of F 2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F 2 , conventional R-factors R are based on F, with F set to zero for negative F 2 . The threshold expression of F 2 > σ(F 2 ) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F 2 are statistically about twice as large as those based on F, and R-factors based on ALL data will be even larger.
2-[3,5-Bis(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl]-4,6-bis(4-fluorophenyl)pyrimidine

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å 2 )
x y z U iso */U eq F1 0.89250 (10) 0.66229 (9) 0.65306 (6) 0.0382 (2) 
